Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
---|---|---|---|---|---|---|
Filed 2025-06-12 16:26 Tx date 2025-06-11 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$154,000
+200,000 vol $0.77 each |
950,000 | |
Filed 2025-06-12 16:24 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares Grant Stock Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2025-06-12 16:16 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$262,500
+750,000 vol $0.35 each |
750,000 | |
Filed 2025-06-12 16:10 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2025-06-12 13:40 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares Grant Stock Options
00 - Opening Balance-Initial SEDI Report
|
200,000 | ||
Filed 2025-06-12 13:40 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares Grant Stock Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2022-04-06 11:15 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2024-05-20 15:40 Tx date 2024-02-05 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$164.00
+200 vol $0.82 each |
6,770,069 | |
Filed 2024-05-20 15:39 Tx date 2024-02-05 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$13,120
+16,000 vol $0.82 each |
6,769,869 | |
Filed 2024-05-20 15:38 Tx date 2023-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,240
+4,000 vol $0.56 each |
6,753,869 | |
Filed 2024-05-20 15:37 Tx date 2023-03-29 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$6,360
+12,000 vol $0.53 each |
6,749,869 | |
Filed 2022-04-06 11:15 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
750,000 | ||
Filed 2022-04-06 11:06 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
6,737,869 |